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Tumor metastases represent the major cause of cancer-related mortality, confirming the
urgent need to identify key molecular pathways and cell-associated networks during the
early phases of the metastatic process to develop new strategies to either prevent or
control distal cancer spread. Several data revealed the ability of cancer cells to establish
a favorable microenvironment, before their arrival in distant organs, by manipulating
the cell composition and function of the new host tissue where cancer cells can
survive and outgrow. This predetermined environment is termed “pre-metastatic niche”
(pMN). pMN development requires that tumor-derived soluble factors, like cytokines,
growth-factors and extracellular vesicles, genetically and epigenetically re-program
not only resident cells (i.e., fibroblasts) but also non-resident cells such as bone
marrow-derived cells. Indeed, by promoting an “emergency” myelopoiesis, cancer cells
switch the steady state production of blood cells toward the generation of pro-tumor
circulating myeloid cells defined as myeloid-derived suppressor cells (MDSCs) able to
sustain tumor growth and dissemination. MDSCs are a heterogeneous subset of myeloid
cells with immunosuppressive properties that sustain metastatic process. In this review,
we discuss current understandings of how MDSCs shape and promote metastatic
dissemination acting in each fundamental steps of cancer progression from primary
tumor to metastatic disease.
Keywords: MDSCs (myeloid-derived suppressor cells), immunosuppression, metastases, metastatic process,
pre-metastatic niche
INTRODUCTION
At steady-state, peripheral myeloid cells, such as monocytes and neutrophils, are constantly
replenished by new cells originated from hematopoietic stem and progenitor cells (HSPCs) located
in the bone marrow (BM) following tightly regulated biological processes (1–4). This constant
turnover, termed myelopoiesis, has a profound impact on the BM activity, since approximately
hundreds of millions of myeloid cells are generated everyday (5). These myeloid effector cells
control localized infections preventing bacterial dissemination without altering the physiological
BM cellular output. In contrast, in the presence of a severe infection, injury and stress, the
release of inflammatory cytokines and chemokines as well as the activation of damage- or
pathogen-associated molecular patterns (DAMPs and PAMPs, respectively) can systemically alter
the development of myeloid cells favoring the generation of a large amount of de novo BM-derived
cells. This abnormal process is termed as “emergency” myelopoiesis (6, 7) and, in clinical settings,
it is characterized by an increased number of neutrophils (neutrophilia) and the presence of
circulating immature myeloid precursors (“left shift”). The overall goal of this time-regulated
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process is the continuous replenishment of myeloid cells
that are consumed in the battle against pathogens until
the return to a steady-state condition. However, this flexible
and powerful system can be corrupted by cancer cells to
establish a stable inflammation state that sustains a long-lasting
altered myelopoiesis (8). For this reason, tumor-promoting
inflammation has been listed among tumor hallmarks (9).
Indeed, by releasing several tumor-derived soluble factors
(TDSFs), such as growth factors [i.e., granulocyte colony-
stimulating factor (G-CSF) and granulocyte macrophage-colony
stimulating factor (GM-CSF)], pro-inflammatory cytokines (i.e.,
interleukin (IL)-6, IL-1β and tumor-necrosis factor (TNF)-
α) (10–12), as well as by tumor-derived exosomes (TEXs)
shedding (13), cancer cells can orchestrate and maintain this
abnormal hematopoietic response. Accordingly, it has been
recently demonstrated that lethally irradiated mice transplanted
with TEX-educated BM cells possess greater number of BM-
derived cells inside the primary tumor mass as well as a greater
metastatic burden than controls, suggesting the ability of TEXs
to manipulate the hematopoietic cell proliferation and lineage
differentiation programs (13). Similarly, several reports highlight
an impairment of the HSPC hierarchy mediated by TDSFs which
reduce the number of quiescent pluripotent stem cells, through
the activation of alternative signaling pathways, promoting the
accumulation of high number of immature and mature cells
in the BM and in the periphery of tumor-bearing hosts (14–
18). In the light of these premises, the increased neutrophil-
to-lymphocyte ratio (NLR), that is a simple clinical parameter
to evaluate systemic inflammation, has been confirmed as a
suitable prognostic and predictive value for patient outcome in
different cancer settings (19, 20). This close relationship between
BM-derived immune cells and cancer cells raises several basic
questions: why do cancer cells orchestrate and promote the
alteration of BM-derived cell generation? Which is the result
of tumor-driven myelopoiesis? Which is the impact of tumor-
educated myeloid cells on tumor progression? Apparently, the
final goal of cancer cells is to generate myeloid partners that fuel
and sustain its growth and spreading and, among them, myeloid-
derived suppressor cells represent the most attractive candidate.
MDSC: A TUMOR-INDUCED MYELOID
CELL SUBSET
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous
myeloid cell population characterized by immune regulatory
properties (21, 22). The differentiation and accumulation of
MDSCs in human beings depends on pathological conditions
such as cancer (23), infection (24), autoimmunity (25) and
transplantation (26) but occurs during physiological processes
such as aging (27) and pregnancy (28). MDSCs can be divided
at least in three main subgroups according to the expression
of selective surface markers: monocytic MDSC (M-MDSCs),
that are characterized as CD11b+Ly6C+Ly6G− cells in mouse
and CD11b+CD14+CD15−HLA-DRlow/−CD124+ cells in
human; polymorphonuclear-MDSC (PMN-MDSCs), that are
identified as CD11b+Ly6C−Ly6G+ cells in tumor-bearing
mice and CD11b+CD14−CD15+HLA-DRlow/−CD124+
cells in cancer patients (when the analysis is performed
in low density mononuclear cell fraction); finally, the last
MDSC subset is composed by “early immature” MDSCs
(eMDSCs) defined as CD11b+Gr1+CCR2+Sca1+CD31+
cells in mouse and Lin−CD11b+CD34+CD33+CD117+HLA-
DRlow/− cells in human (8, 21, 29). Since MDSCs share
some phenotypic and morphologic features with the normal
counterpart (i.e., neutrophils and monocytes) (22), their
unequivocal identification needs to be proved by functional
in vitro assays (22, 30). In fact, we recently demonstrated that,
immunosuppressive monocytes isolated from the blood of
pancreatic ductal adenocarcinoma (PDAC) patients resembling
M-MDSCs, were not distinguishable from normal monocytes
by the expression of a specific surface markers but, instead,
by cytological features (i.e., smaller size, presence of granules),
immune suppressive properties and molecular signatures (31),
suggesting the existence of a high heterogeneity and complexity
among the M-MDSC subsets. Similarly, the discrimination
between PMNs and PMN-MDSCs based on differential
expression level of surface markers has recently generated a
lot of controversies [as discussed in (32, 33)] suggesting that
only a complementary analysis of genomic, proteomic, and
biochemical characteristics would precisely pinpoint the target
cell population. Even if several phenotypic markers have been
proposed to be exclusive of MDSCs [i.e., CD38 (34), TNFR (35)],
so far none of them has been proved has unequivocal target for
MDSC [as recently reviewed in (22, 36)]. Only the expression of
the lectin-type oxidized LDL receptor 1 (LOX-1) was reported to
be exclusive of PMN-MDSCs (37), but more studies in different
patient cohorts need to be done.
In general, M-MDSCs are more immunosuppressive than
PMN-MDSCs on a per cell basis both in tumor-bearing
mice (15, 38) and cancer patients (31). Moreover, M-MDSCs
exhibit longer half-life and more pronounced cell plasticity
compared to PMN-MDSCs since they are able to differentiate
into tumor-associated macrophages (TAMs) (39), as well as
they can act as “precursors” to maintain circulating PMN-
MDSCs level (38). Indeed, in tumor-bearing but not in tumor-
free mice, M-MDSCs acquire PMN-MDSC-associated features
through an epigenetic mechanism based on downregulation
of retinoblastoma protein expression by histone deacetylase
enzymes (40). Notably, M- and PMN-MDSCs display also
distinctive cell-death programs. In fact, the anti-apoptotic
molecules c-FLIP (cellular FLICE [FADD-like IL-1β-converting
enzyme]-inhibitory protein) and MCL-1 are essential for the
development of M-MDSCs and PMN-MDSCs, respectively (41).
Interestingly, we recently demonstrated that c-FLIP plays an
essential role on re-programming exclusively monocytes into
MDSCs without affecting cell survival since this mechanism
does not affect neutrophils conversion into PMN-MDSCs. In
addition, we unveiled c-FLIP as a new regulator of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-
κB) signaling by interaction with the p50 subunit in the
nucleus therefore promoting the aberrant transcription of
several immunosuppression-related genes (42). Nowadays, in
the single-cell omics era, it is quite accepted that M-MDSCs
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and PMN-MDSCs represent the two major extremes of a
continuous spectrum of myeloid cells differentiation induced by
tumor and only the application of high resolution transcriptome
technologies will shed light on the ontogeny of the complex
and variegated world of MDSC. In line, recent publications
clearly showed that MDSCs originate “unexpected” cell subsets
like dendritic cells (DCs) (43) or fibroblasts (44) in response to
diverse microenvironmental stimuli.
The MDSC plasticity and functions are strictly guided by the
activation of precise signaling pathways [extensively reviewed
in (8, 45)] preferentially driven by c/EBPβ (CCAAT/enhancer-
binding protein) (16), STAT3 (signal transducer and activator of
transcription 3) (31, 46) and NF-κB (42, 47) transcriptional
factors. c/EBPβ is the master regulator of “emergency”
myelopoiesis and its critical role on MDSC biology was proved
using myeloid-restricted c/EBPβ-deficient mice engrafted with
different tumor models in which the ontogeny and MDSC-
associated immunosuppression were completely abrogated
(16). Recently, Strauss and collaborators demonstrated that
c/EBPβ-guided myelopoiesis can be sustained by myeloid-
specific expression of the retinoic-acid related orphan receptor
(RORC1/RORγ) (17) promoting MDSC and TAM expansion.
Furthermore, MDSC generation and accumulation in tumor-
bearing mice can also be driven by the c/EBP homologous
protein (CHOP)-mediated signaling (48). CHOP is the master
sensor of endoplasmic reticulum (ER) stress such as low
pH, high levels of reactive oxygen species (ROS, i.e., H2O2),
nitric-oxide (NO), hypoxia, nutrient deprivation, etc. (49).
Interestingly, ER stress-inducers like thapsigargin promote in
vitro differentiation of human neutrophils to PMN-MDSCs (37).
Similarly, GCN2 (general control non-derepressible 2), that is a
master environmental sensor able to control transcription and
translation in response to nutrient availability, was reported
to drive and sustain immunosuppressive functions of MDSCs
in tumor microenvironment (50). STAT3 plays a central role
in regulating both the expansion and the tolerogenic effects
of MDSCs. STAT3 preserves MDSC survival by upregulating
B-cell lymphoma XL (Bcl-XL), c-Myc, Cyclin D1 and survivin
(51, 52), and by blocking myeloid cell differentiation through
the downregulation of interferon regulatory factor (IRF)
8 expression (53). STAT3 controls many MDSC-released
mediators (cytokines, growth factors, enzymes) that promotes
pro-tumor effects. In particular activated STAT3 triggers on
one hand the production of pro-inflammatory proteins, like
S100A8/A9 (54) that interfere with DC differentiation and
sustain ROS generation (55); on the other hand by binding
to the arginase 1 (ARG1) promoter, STAT3 favors its aberrant
expression (46). Interestingly, we recently demonstrated a
unique STAT3-dependent expression of ARG1 in a subset of
cancer patient-derived monocytes (31). NF-κB, the master
regulator of inflammation, was reported to be involved in
MDSC differentiation. Recently, Sangaletti and collaborators
demonstrated that impaired translocation of NF-κB p50 protein
abolishes the secretion of protein acidic and rich in cysteine
(SPARC) and alters MDSC-associated immunosuppression by
limiting ROS production. Indeed, restricted p50 translocation
into nucleus limits the formation of the immunosuppressive
p50:p50 homodimers in favor of the p65:p50 inflammatory
heterodimers that sustain an increased release of TNFα in
the tumor microenvironment (47). According to this, we
demonstrated that, the enhancement of nuclear p50 translocation
by c-FLIP promotes acquisition of immunosuppressive function
by monocytes (42). Together, these data highlight a pivotal role
of p50 on driving MDSC differentiation that needs to be better
investigated in the near future.
Classically, MDSC pro-tumor functions are ascribed for the
effects on the adaptive immune response. However, recent
insights on MDSC field demonstrated that these tumor-educated
cells sustain tumor growth by also non-immune processes such
as by promoting angiogenesis, maintaining cancer cell-stemness
and sustaining the metastatic process. Since metastatic spreading
is essentially inefficient whereby the majority of cancer cells
cannot rich or seed to distant sites, tumors need to develop
strategies to both inhibit immune response and alter tissue
framework. Thus, in this context, it is clear thatMDSCs represent
the best partner for tumor cells since circulating MDSCs can
support tumor cell during each step of the metastatic process.
MDSCs INVOLVEMENT DURING
DIFFERENT STAGES OF METASTATIC
PROCESS
Metastasis is a stepwise process that drives cancer’s outgrowth to
an organ different from which they originated. Indeed, cancer
cells, after acquiring an invasive phenotype by accumulation of
genetic and epigenetic aberrations (primary tumor growth), can
invade the surrounding tissues (local invasion) and infiltrate into
the blood stream or lymph vessels (intravasation) turning into
anchorage-independent circulating tumor cells (CTCs). After
intravasation, CTCs need to stay alive (survival in circulation)
until they exit from the circulation (extravasation) and adapt
themselves to a new tissue (pre-metastatic niche) to generate a
secondary tumor mass (metastasis formation) (56, 57) as depicted
in Figure 1. Here we will describe the role of MDSCs on the
different steps of the metastatic cascade.
MDSCs Promote Primary Tumor Growth
and Local Invasion
MDSCs promote primary tumor progression by both
immunological and non-immunological mechanisms (8, 29).
The immunological pro-tumor functions of MDSCs is exploited
by suppressing both innate and adaptive immune responses.
Indeed, MDSCs support the generation of a hostile tumor
microenvironment by producing metabolites and soluble
factors, as well as by expressing membrane-bound proteins
which interfere with effector T cell function and fitness (58)
or by promoting the generation of Foxp3 (forkhead box P3)-
expressing immunosuppressive B regulatory (Breg) (59) and T
regulatory (Treg) lymphocytes (60) as summarized in Figure 2.
In this context, the depletion of essential aminoacids, such as
arginine, tryptophan, cysteine and glutamine represents a key
strategy (61). MDSCs co-express ARG1 and inducible nitric
oxide synthase (iNOS, NOS2), which compete for the same
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FIGURE 1 | MDSCs contribution to the different steps of the metastatic cascade. MDSCs promote primary tumor growth and local invasion (1) with several
mechanisms including suppression of adaptive immune response, ECM reorganization, promotion of epithelial-mesenchymal transition as well as maintaining tumor
cells stemness. MDSCs also support distal tumor spread by favoring tumor cells intravasation (2), CTC survival in circulation (3) and CTC extravasation at the
metastatic site. Moreover, MDSCs contribute to the formation of the pre-metastatic niche (5) in which CTC can proliferate promoting the metastasis formation (6).
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FIGURE 2 | Immune suppressive functions of MDSCs on NK cells and T-cells. MDSCs inhibit immune effector cells by exploting four main mechanisms: (A) MDSCs
deplete essential metabolites for T lymphocyte fitness (i.e., L-arginine, L-tryptophan, L-cysteine, and L-glutamine) which induce T cell proliferation arrest. L-arginine
depletion, promoted by ARG1 activity, induces the loss of the CD3ζ chain affecting T cells response to various stimuli. The kynurenines, produced during L-tryptophan
catabolism by IDO, block NK cells proliferation, activation and functions. (B) MDSCs produce ROS and RNS. The release of NO inhibits FC-receptor-mediated ADCC
in NK cells and reduces their effector functions. High levels of ROS downregulate CD3ζ chain expression and reduce cytokine secretion on T cells. RNS also block T
cells recruitment and proliferation by nitration/nitrosylation of chemokines (CCL2, CCL5, CCL21, CXCL12) and TCR. (C) MDSCs suppress NK cells and T cells by
direct contact. MDSCs, through membrane-bound TGF-β and NKp30L, promote NK cell anergy. MDSCs block the T cell homing through CD62L/ADAM17
interaction; moreover, MDSCs express PD-L1 and FAS-L, which binding their receptors on T cells, promote T-cell apoptosis. (D) MDSCs induce immune suppression
through the release of soluble factors: MDSCs present high levels of CD39 and CD73 able to transform ATP in adenosine. High amount of adenosine affect NK
maturation as well as NK and T-cell effector functions. Moreover, by TGF-β release, MDSCs induce Treg cells and reduce IFNy, TNFα, and GRZ release by NK cells.
substrate, arginine, in order to produce ornithine and urea or
NO and citrulline, respectively (62). Arginine depletion reduces
the expression of cyclin D3, cyclin dependent kinase 4 (cdk4),
and E2F1 transcription factor in T cells favoring their cell cycle
arrest in G0-G1 phase and anergy (63). Moreover, the reduced
arginine availability affects the TCR ζ-chain expression in T
lymphocytes, limiting thus their activation, proliferation and
cytokine production (64). Interestingly, some polyamines (i.e.,
spermidine) produced by ARG1-dependent pathway activate
indoleamine 2,3-dioxygenase 1 (IDO1) expression and signaling,
thus constituting keys elements for the crosstalk between
these two enzymes (65, 66). IDO1 is the most up-regulated
tryptophan (Trp)-catabolizing enzyme in tumor-infiltrating
MDSCs and tolerigenic DCs (67). IDO1 catabolizes Trp into
NAD+ (nicotinamide adenine dinucleotide), an essential
pyridinenucleotide that orchestrates several cell-associated
biological processes, through the production of kynurenines
(68). The latter, by binding to the aryl-hydrocarbon receptor,
promote both T lymphocytes and antigen presenting cells
(APCs) switch into Tregs and IDO1-expressing tolerogenic
DCs, respectively (69). Similarly to the effect of arginine
depletion, Trp consumption was shown to promote the down-
regulation of TCR ζ-chain favoring T cell anergy (70). Moreover,
kynurenine accumulation was reported to inhibit NK cell
function and proliferation (71). When the physiological amount
of arginine in the tumor microenvironment drastically decreases,
iNOS generates superoxide anion (O−2 ) by a biochemical
process called “uncopling reaction” (72). This unstable agent
rapidly produces aberrant reactive nitrogen species (RNS)
such as peroxinitrites (ONOO−). RNS promote protein post-
translational modifications (PTMs) which irreversibly alter
protein functions. PTMs finely tune the immune response in the
tumor microenvironment by affecting different T cell-dependent
signaling pathways and biological processes. Indeed, PTMs
modifying both chemokines (i.e., C-C chemokine ligand 2 and
5, CCL2 and CCL5) and immune receptors (i.e., peptide-MHC
complex, pMHC), damp both T lymphocyte migration toward
primary tumor site (73) and T cell activation and persistence (74),
respectively. In fact, tumor-bearing mice treated with AT38 ([3-
(aminocarbonyl) furoxan-4-yl] methyl salicylate), an ARG1 and
iNOS transcriptional inhibitor, displayed a strong reduction of
nitro-tyrosine (NTy)-based PTMs in tumor microenvironment
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favoring T-cell infiltration inside the tumor and improving
anti-tumor immunotherapy (73). Similarly to RNS, high
amounts of ROS and NO in tumor microenvironment reduce
also antigen specific T cell response by affecting TCR-associated
(75, 76) or IL2R-dependent (77) signaling pathways. Moreover,
MDSC-released NO reduces Fc receptor-mediated antibody-
dependent cellular cytotoxicity (ADCC) of NK cells and alters
their effector functions inhibiting IFNγ and TNFα secretion (78).
The production of ROS by MDSCs preferentially depends on
NADPH oxidases (NOX family) (79) and promotes the activation
of several inflammatory target genes such as cyclooxygenase-2
(COX-2) (80). Notably, the inhibition of ROS generation
through the addition of either catalase, an enzyme that detoxifies
hydrogen peroxide, or Celecoxib, a COX-2 inhibitor, effectively
impaired the MDSC immunosuppressive function in vitro
(81, 82). Recently, we demonstrated that ARG1 has a hierarchical
negative function as compared to iNOS in establishing an
immunosuppressive tumor microenvironment since tumor-
infiltrating, iNOS-expressing myeloid cells (defined as Tip-DC)
efficiently sustain anti-tumor T cell activities on debulking tumor
mass (83). The pro-tumor role of ARG1 was partially confirmed
by clinical evidences. Indeed, the frequency of ARG1-expressing
MDSCs significantly discriminate PDAC metastatic patients
suggesting that these cells have a pro-metastatic potential
(31), as well as the reduction of ARG1+ cells in melanoma
patients after Ipilimumab-based treatment highlights that the
therapeutic efficacy of this immune-based treatment might
involve a systemic effect on MDSC accumulation (84). Indeed, a
contraction of MDSCs in a Durvalumab responder patient was
also reported in lung adenocarcinoma setting (85), suggesting
that MDSC enumeration might be a useful biomarker to stratify
immunotherapy-undergoing patients. All these evidences will
be validated in a large number of immunotherapy-based clinical
trials in the next years.
Another MDSC-associated strategy to inhibit T cells depends
on the release of soluble factors, especially anti-inflammatory
cytokines. Tumor growth factor (TGF-)-β for instance suppresses
CD4-expressing T helper (Th) lymphocyte differentiation toward
Th1 and Th2 phenotype by altering T-bet and GATA3 expression
(86–88). Moreover, TGF-β in association with either IL-
10 or specific cell-to-cell contacts [i.e., CD40/CD40L (89)]
promotes not only the conversion of naïve T cells into Tregs
(90) but also the macrophage polarization toward M2 status
through an autocrine positive loop (91). Furthermore, MDCSs
induce NK cells anergy through the membrane-bound TGF-
β (92). Interestingly, TGF-β-produced by MDSCs promotes
the expression of programmed cell death-1 (PD1) in T cells
(93). Similarly, MDSCs can hinder T cell fitness and function
by directly binding FASL and PDL1 with respective death
receptor ligands expressed on T cell surface (94, 95). In this
context, for example, the β2 adrenergic receptor triggering
induces STAT3-mediated up-regulation of death receptor ligands
in MDSCs, potentiating their T cell dysfunction abilities (95).
Notably, the transcriptional expression of PDL1 in MDSCs is
strictly controlled by TDSFs such as vascular endothelial growth
factor (VEGF) and macrophages colony-stimulating factor (M-
CSF) (96) as well as by hypoxia-inducible factor (HIF-)1α
signaling pathway (97). Interestingly, the activation of HIF-
1α in MDSCs favors also the expression of ectonucleoside
triphosphate disphosphohydrolase 2 (NTPDase2/CD39L1), an
ectoenzyme that controls MDSCs accumulation (98) as well as
the expression of (NTPDase1/CD39) and ecto-5′-nucleotidase
(Ecto5’NTase/CD73) directly involved in the generation of
extracellular adenosine (99), known inhibitor of T cell activation
by Zap70-, ERK- and Akt-associated pathway blockade (100)
and NK effector functions reducing granzyme, IFNγ and TNFα
release (101).
By exploring all these multiple immune-related mechanisms,
MDSCs generate a physical and chemical shield against T
lymphocytes that protects cancer cells. However, MDSCs are also
actively involved in non-immunological processes that sustain
tumor local invasion by altering directly tumor cells or the
tissues around. In fact, the uncontrolled tumor growth implies
profound changes in the adhesion and migratory properties
of the tumor cells, which favor cellular dissociation and
migration to adjacent tissues, as well as key alterations of tissue
framework such as extracellular matrix (ECM) composition.
To sustain tumor progression, MDSCs can drive tumor cells
to lose epithelial features and the gain of a mesenchymal
phenotype, a process known as epithelial-to-mesenchymal
transition (EMT), through the release of soluble factors (102).
In melanoma bearing mice, in fact, PMN-MDSCs induce EMT
by releasing TGF-β and hepatocyte growth factor (HGF) (103);
moreover EMT was finely tuned by MDSC-secreted factors
such as TGF-β release in combination with high amount
of NO in nasopharyngeal carcinoma (104). Moreover, both
MDSCs and tumor cells secreted high-mobility group box-1
(HMGB1), a damage-associated molecular pattern protein whose
signaling trough both Toll-like receptors (TLRs) and receptor
for advanced glycation end products (RAGE), activates EMT-
inducing transcription factors (i.e., Snail and NF-κB) and up-
regulates matrix metalloproteinase-7 (MMP7) (105). However
HMGB1 is a pleiotropic molecule that shows pro-tumor and
tumor-restricting actions in a context specific manner (106,
107). MDSCs are also capable to preserve cancer cell intrinsic
properties such as cellular stemness. For instance, the direct
contact between MDCSs and ovarian cancer cells induced a
stem-like phenotype in tumor cells and enhanced their ability
to metastasize in vivo. This effect is mediated by microRNA-101
up-regulation in neoplastic cells and the subsequent inhibition
of the co-repressor gene C-terminal binding protein-2 (CtBP2),
which modulates the expression of stem cell genes (108). PMN-
MDSCs can also block senescence in cancer cells by promoting
their growth through the release of IL-1 receptor antagonist (109)
or S100A9-expressing exosomes (110). Finally, in both mouse
and human pancreatic tumors, M-MDSCs induce the expansion
of aldehyde dehydrogenase-1 (ALDH1)–expressing cancer stem
cells that are characterized by higher metastatic potential (111).
Furthermore, MDSCs can actively support tumor progression
by acting on the physical framework of local tissue. Indeed,
MDSCs support tumor invasion by ECM remodeling and
rearrangement of the epithelial basement membrane as well
as by modifying matrix stiffness (112). ECM is composed
of different macromolecules including collagens, fibronectin,
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laminin, proteoglycans and polysaccharides and regulates many
cellular functions such as cell adhesion, proliferation and
migration (113). This complex structure can be remodeled by
both tumor cells and MDSCs that release high amounts of
degrading enzymes such as MMPs and cathepsins (114, 115).
Indeed, MDSCs produce high levels of MMPs, including MMP2,
MMP8, MMP9, MMP13, and MMP14, which by digesting ECM
allow tumor cells migration (116). Furthermore, the remodeling
of ECM increases the bioavailability of matrix-bound factors
such as TGF-β and VEGF which further prompt tumor cell
invasiveness and angiogenesis (114, 117). Notably, MDSC-
released TGF-β induces the production of lysyl oxidase (LOX),
which cross-links collagen fibers and other ECM components.
LOX overexpression in breast cancer increases ECM stiffness
which could promote tumor cell invasion and intravasation
by enhancing integrin-dependent mechanotransduction (118,
119). Moreover, ECM structure and composition can influence
many aspects of MDSC behaviors, including infiltration,
differentiation, and function generating a sort of vicious cycle
that favors tumor growth and dissemination (113). In light of
these evidences, it is not surprising that SPARC, a matricellular
protein produced by tumor cells, promotes the expansion and
recruitment of MDSCs (120). In turn, the ablation of SPARC
in PMN-MDSCs reduces their suppressive activity and their
capacity to sustain EMT and tumor growth (47). Similarly,
silencing osteopotin (OPN), a matrix protein, in 4T1 breast
cancer cells prevents metastasis development by affecting M-
MDSC suppressive activity but not their recruitment at the
metastatic site (121). The complement system plays also a
pivotal role in promoting the metastatic spread by regulating
the recruitment of myeloid cells and MDSCs in lung and
regulating the release of IL10 and TGF-β with subsequent
suppression of effector CD8 and CD4T lymphocytes and
induction of Treg generation (122) in a breast cancer preclinical
model. Moreover, in absence of tumor specific T cells, the
anaphylatoxin C5a promotes tumor growth by recruiting and
activating myeloid-derived suppressor cells to release NO and
ROS (123, 124). However, it was recently demonstrated that C3a
and C5a have a pleiotropic and context specific role in tumor
progression. Indeed the activation of the complement on tumor
endothelium abrogates tumor endothelial barrier and restores T
cell infiltration in tumor bed, especially in the presence of a tumor
specific T cell response, improving thus adoptive T cell therapy
efficacy (125, 126).
MDSCs Favor Tumor Cells Intravasation
Into Circulation
Following migration through the ECM, cancer cells should
intravasate in the blood or lymphatic circulation. Therefore,
within the primary tumor the promotion of new vessels
formation appears as a key point for tumor cells dissemination.
MDSCs can participate to this process inducing the development
of a dysfunctional vasculature that is more permissive to tumor
cell intravasation, as we will discuss later. Moreover, through
the release of proteolytic enzymes such as MMP2 and MMP9,
MDSCs can remodel the basal membrane, opening a route for
neoplastic cell migration (127). For instance, tumor activated
PMNs, recruited through HMGB1 produced by UV-damaged
epidermal keratinocytes, promote cancer cell transmigration and
enhanced metastasis (128).
However, the metastatic potential of CTCs depends on their
ability to extravasate and colonize distant organs. In both
melanoma and sarcoma models, tumor cells are trapped in
capillaries due to size-restriction; however, also in the absence
of a physical barrier CTCs can stop forming active adhesions
to the endothelium (129). The balance between pro- and anti-
tumoral inflammation appears as a crucial step of this process.
Although NK cells and macrophages are capable to mediate
the clearance of CTCs, myeloid cells activated toward a pro-
tumorigenic phenotype can promote cancer cell survival and
favor their adherence to the endothelium, boosting extravasation
(56). Indeed, in both melanoma and liver cancer, PMN-MDSC-
like cells can increase tumor cell retention and transendothelial
migration by integrin (MAC-1)/ICAM-1 interaction (130, 131).
Finally, both neutrophils and inflammatory monocytes (iMos),
that in cancer setting resemble MDSCs (132), can physically
associate with cancer cells supporting their extravasation (133).
MDSCs Protect CTCs in Circulation and
Promote Their Extravasation
Following shedding from the primary site, tumor cells enter
the blood stream where they encounter an unfavorable
environment created by the mechanical and physical sheer
forces present inside the vessels (134, 135). Once entered
the blood, the CTCs have to face a second challenge: they
must escape the immune surveillance. One option to avoid
the fatal encounter is to generate clusters. CTC clusters have
been detected both in tumor-bearing mice and in cancer
patients, and even though they represent a minority (2–4%)
of the entire CTC population, they have higher probability
to generate metastases than “lonely” CTCs (136). The CTC
clusters escape the immune surveillance by physically interacting
between themselves (homotypic interaction) or with leukocytes
(heterotopic interaction). In this context Szczerba et al. (137)
demonstrated that almost 50% of breast cancer patients have
detectable CTCs in the blood, and among them, a small subset
(3.4%) was composed by CTCs coupled with leukocytes. Through
a single cell transcriptomic profiling, the authors demonstrated
in several breast cancer preclinical models and cancer patients
that these clusters comprise neutrophils with a N2-like signature,
resembling PMN-MDSCs expressing ARG1, chemokine (C-
X-C motif) ligand 2 (CXCL2), CCL2, VEGFA and endowed
with pro-tumoral activity. A compelling finding was that CTC-
neutrophil clusters led to fast metastases and short survival
in mice and their presence correlated with poor prognosis in
cancer patients. These results implied that neutrophils-associated
CTCs gain a more aggressive phenotype than their homotopic
cluster counterparts, which is linked to and increased mutational
burden mediated by PMN-MDSC-derived ROS, on one side,
and to an increased proliferation conferred by neutrophil-
derived IL-6 and IL-1β on the other one. At levels below the
genotoxic effect, ROS act indeed as mitogenic factor through
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the activation of NRF2-ARE-Notch axis (138–141). Particularly,
it was shown that melanoma and breast patient-derived CTCs
co-cultured with PMN-MDSCs activate Notch signaling via the
direct interaction between Notch1R, present on the surface of
CTCs, and Jagged1/DLL (Notch1 ligands) expressed on PMN-
MDSCs (142). Interestingly, the concomitant activation of Notch
signaling and ROS (i.e., H2O2) synergizes in enhancing CTC
proliferation, in vitro. Thus, PMN-MDSCs sustain CTC survival
through the activation of ROS-NRF2-ARE axis and Notch
signaling pathway. Several mechanisms have been proposed to
be involved in PMN-MDSC-CTC cluster formation. Two of these
were identified on ICAM-1, expressed in CTCs and binding β2-
integrin on neutrophils, and on VCAM-1 (137). Thus, ICAM-1
and VCAM-1 could represent good candidates to interfere with
CTC-PMN-MDSC cluster formation and could be exploited to
prevent metastasis formation. However, the feasibility of this
innovative targeting approach needs to be validated by extensive
experimental data, since the ICAM/VCAM axis is essential for
several physiological processes.
Even though CTCs exploit different strategies to survive
in circulation, their metastatic potential relies on the ability
to extravasate and reach new tissues. While cancer cells are
physically restrained in small venules, the extravasation from big
vessels requires an active process supported by immune cells.
For instance, the neutrophil extracellular traps (NETs), released
by PMN-MDSCs, clog CTCs to favor their adherence to the
endothelium supporting their extravasation and invasion (143).
Thus, we can envision that preventing NET formation could
block CTC-PMN-MDSC cluster formation. While the formation
of NET favors the arrest of CTCs and their physical interaction
with endothelial cells, PMN-MDSC can also potentiate tumor cell
extravasation by directly increasing vessel permeability through
the release of pro-inflammatory factors (i.e., IL-1β, MMP8,
MMP9) and VEGFA, respectively (144, 145). Obviously, a large
number of studies are needed for the development of NET-
targeting approaches to avoid possible side-effects such as a limit
response against pathogens.
MDSCs Role on Generating Pre-metastatic
Niche
For the colonization of metastatic site by cancer cells, a
specific permissive microenvironment, defined as pre-metastatic
niche (pMN), should be pre-established in distant organ [as
extensively reviewed in (146, 147)]. The idea that tumor extrinsic
determinants are actively involved on the preparation of a
supportive environment before CTCs coming, was firstly proved
by R.N. Kaplan and colleagues in 2005. In this pioneering
study, the authors demonstrated that the infiltration of VEGFR-
expressing immature myeloid cells induces the transformation of
healthy tissues to future metastatic sites since these immature
myeloid cells reach the distal metastatic site before the arrival
of cancer cells (148). In fact, tumor-bearing mice display an
increased amount in periphery of Lin−Sca1+cKit+ immature
proliferating cells, that resemble BM-resident HSPCs, suggesting
that tumors promote a reduced BM homing compared to
tumor-free mice. These circulating pro-metastatic cells express
in their membrane surface high amount of α4β1 integrins (also
defined VLA-4) that mediate their arrest into fibronectin-rich
environment in which pMN will be set up (148). Interestingly,
the impact of immature myeloid cells on pMN establishment
has also been confirmed in human setting. Indeed, Karaca et al.
demonstrate that VEGFR-expressing myeloid progenitors are
able to colonize sentinel lymph nodes before the arrival of CTCs
(149). These circulating immature cells differentiate in mature
CD11b+ cells (both CD11b+Ly6G+ and CD11b+Ly6Chigh cells
resembling M- and PMN-MDSCs, respectively) in distal tissues,
generating a “muﬄe and fertile” soil where cancer cells can
growth and expand (148). Therefore, the final differentiation
of myeloid progenitors in pMN-MDSCs occurs mainly at the
periphery rather than in the BM (150). Several TDSFs have been
reported to steer the accumulation and expansion of myeloid
precursors in pMNs (151). As known G-CSF, GM-CSF and
IL-6 strongly influence MDSC differentiation and can also be
used for in vitro MDSC culture (15, 16). Besides the effect
on MDSC differentiation, GM-CSF is proven to be crucial for
MDSC recruitment and accumulation at the tumor site (15,
18) while its role on pMN-development seems to be model-
dependent (152). In contrast, G-CSF is sufficient to trigger
MDSC infiltration in the lung in order to establish pMN,
in breast tumor-bearing mice (153). Indeed, G-CSF mobilizes
bombina variegate (Bv8)-producing CD11b+Ly6G+Ly6C+ cells
that actively sustain pMN generation (152). The myeloid
precursors differentiation into functional immunosuppressive
MDSCs during pMN generation was recapitulated in vitro
using cancer-cell derived supernatants highlighting the key role
of forms like tyrosine kinase 3 (FLT3)-ligand, produced by
cancer cells on sustaining this myeloid cell conversion (150).
A number of tumor-derived chemokines can drive MDSCs
infiltration into healthy tissues and support pMNs formation.
CCL2 produced both in the target organ and in tumor can
promote M-MDSC (defined as CD11b+CD115+Ly6Chi cells)
recruitment to the metastatic niche (145). More importantly,
interfering the accumulation of these cells using a specific
CCL2-blocking antibody strategy, prevent metastases generation
(145). Both cancer and stroma cells contribute in MDSC
accumulation in a CCL2-dependent manner. Increased cancer-
derived CCL2 secretion is often triggered by genetic aberrations
and dysregulated transcriptional program; in fact, p53 deletion
and subsequent Rb protein inactivation in mouse sarcoma
models switch on CCL2 production (154). Likewise, 1Np63
transcriptional factor, which is often up-regulated in cancer
cells, could directly induce CCL2 and CCL22 expression and
the following metastatic spread by myeloid cell accumulation
(155). Besides cancer cells, also cancer-associated fibroblasts
(CAFs), characterized by the expression of fibroblast activation
protein (FAP-)α, release high amount of CCL2, leading to
sustain MDSC infiltration in pMNs (156). Interestingly, in
intrahepatic cholangiocarcinoma patients, high levels of FAP
have been associated with a worse metastatic prognosis (156).
In colorectal cancer mouse model, instead, high amounts of
CXCL1 released by TAMs have been reported to attract CXCR2-
expressing MDSCs to generate liver pMNs (157). Other studies
reported additional chemokines promoting MDSC transport to
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pMNs, such as MCP-1 (monocyte chemoattractant protein 1)
(158), CCL12 (159), CCL9 (160), CCL15 (161), and CXCL17
(162), although the source of these cytokines in pMNs remains
often unclear. Nowadays there are accumulating evidences that
pro-metastatic molecules can be transported not only as soluble
factors, but also inside tumor-derived microvesicles such as
TEXs (13, 163, 164). Indeed, TEXs expressing distinctive integrin
patterns guide the organotropism of metastases by orchestrating
metastatic distribution and favor the generation of pMN by
fusing themselves with resident cells (165). By a preferential
tissue distribution, TEXs transfer their cargos, containing
proteins, genetic materials and metabolites, to reprogram and
educate pMN resident cells. MicroRNA (miR)122-derived from
breast carcinoma TEXs, by inhibiting glucose uptake in non-
tumor resident pMN cells, promote brain metastases (166).
Moreover, MIF (macrophage migration inhibitory factor)-loaded
pancreatic TEXs, promoting macrophages recruitment into
liver pMNs, exacerbate liver metastatic burden (167). Similarly,
TEXs mediate the production of pro-inflammatory S100A8
and S100A9 by pMN-resident endothelial cells that favors
the expression of serum amyloid A (SAA)3 able to recruit
CD11b-expressing myeloid cells by a TLR4-dependent pathway
(168). Importantly, MDSCs can also synthesize and secrete high
amounts of S100A8/A9 dimers (169) and exosomes derived
from Gr1+CD11b+ MDSCs are able to carry these proteins
(170). These findings suggest that S100A8/A9 factors maintain
an autocrine feedback loop that favors accumulation of MDSC
in pMNs. Indeed, S100A8/A9 molecules are important players
in metastases generation by favoring both recruitment and
differentiation of several pMN-infiltrating myeloid cell subsets
commonly defined as Mac-1+ myeloid cells among the MDSCs
(168, 169). In agreement with this, S100A9-deficientmice showed
a strong impairment of MDSCs accumulation in liver and
lung pMNs during colon metastatization (171). Exosomes could
also transport signaling molecules from MDSCs to the other
components of pMN, but this crosstalk is poorly characterized
and needs further investigation.
In order to become available for colonization by CTCs, distant
pMNs undergo several tissue alterations such as the generation
of new blood vessels that provide oxygen and nutrients to
proliferating cancer cells (146, 147). This process is termed
’angiogenic switch’ and, in general, it is promoted in response
to hypoxia (172). MDSCs play a critical role on initiating
and sustaining the development of a new vascularization in
pMN, primarily by secreting a variety of regulatory molecules
such as VEGFA (173). Recently, Hsu et al. demonstrated that
high amount of platelet-derived growth factor BB (PDGF-BB)
released by pMN-infiltrating MDSCs increases angiogenesis and
chaperone tumor cells through the bloodstream to new sites
of metastasis (162). Another MDSC-associated proangiogenic
factor is Bv8, which is released by a STAT3-dependent
pathway (174, 175). The pro-tumor impact of Bv8-expressing
MDSCs is confirmed by the high amount of these cells in
tumor-bearing hosts undergoing refractoriness to anti-VEGF
therapy (176). Similarly, MDSCs mediate also resistance to
the antiangiogenic sunitinib, a tyrosine kinase inhibitor, both
in preclinical (177) and clinical (178) settings of renal cell
carcinoma. pMN-infiltrating MDSCs sustain angiogenesis also
by producing high levels of MMP9 that promotes bioavailability
of VEGF. Indeed, the genetic ablation of Mmp9 restricts
metastasis formation by normalizing the aberrant vasculature in
pMNs (179). Interestingly, liver metastases-infiltrating MDSCs
induce also the down-regulation of the antiangiogenic factor
angiopoietin-like 7 (ANGPTL7) in cancer cells (180). During
pMN establishment, MDSCs can also acquire some unexpected
properties and features. Indeed, several studies reported the
presence of an alternative MDSC subtype termed fibrocytes in
patients with metastases (181, 182). Ou et al. demonstrated
that fibrocytes can be generated in mouse cancer models from
CD11b+Ly6G+ MDSC subset following a Kruppel-like factor
4 (KLF4)-dependent signaling (183). Moreover, MDSCs can
undergo osteoclast differentiation and contribute to enhanced
bone destruction and tumor growth in both breast cancer and
myeloma models (184–186). Nowadays, the main knowledge
about the role of MDSCs in pMN generation is derived
from different mouse models in which cancer-cell derived
factors, that support MDSC recruitment to pMN, have been
studied broadly. Therefore, both the genetic and the epigenetic
MDSC-reprogramming as well as the definition of key MDSC-
associated properties during pMN development need to be
deeply elucidated.
MDSCs Involvement During Metastases
Formation
Since most metastases present epithelial but not mesenchymal
features, probably the EMT process is a temporary occurrence,
and tumor cells, after seeding in pMN, revert their phenotype.
This process is termed mesenchymal-to-epithelial transition
(MET). MDSCs are actively involved in this process. In fact, in
lung pMNs of MMTV-PyMT spontaneous breast cancer model,
MDSCs secrete versican, an extracellular matrix chondroitin
sulfate proteoglycan, that sustain MET process by reducing
Smad phosphorylation in cancer cells (187). Interestingly, the
frequency of versican-expressing intratumoral stromal cells
correlates with a worse prognosis in women with node-negative
breast cancer (188).
In contrast, MDSCs may also inhibit metastases. A single
study reported that thrombospondin 1 (TSP-1)-expressing
MDSC-like cells are able to abrogate the metastatic spread
of prostate cancer cells (189) opening new insight on MDSC
and metastasis relation. In the metastases framework, MDSC-
associated immunosuppressive functions are regulated by
oxidative stress and amino acid metabolism (8). MDSCs
rely on fatty acid-β oxidation (FAO) to fuel the synthesis
of inhibitory cytokines (i.e., IL-10, TGF-β) (190), which are
generally required to both restrain T lymphocytes anti-tumor
response and sustain tumor cell aggressiveness thus favoring
metastases. In a recent publication (191), Hsu et al. demonstrated,
in the 4T1 mouse breast cancer model, that the expression
of Csf3 by tumor cells is heterogeneous, with some 4T1 cells
producing higher amounts (i.e., liver metastatic) than others
(i.e., lung metastatic). CSF3 is functionally required for both
maturation, proliferation and mobilization of neutrophils, and
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for the first time Hsu et al. demonstrated that among them, the
low density neutrophils (LDNs), with characteristic ofMDSC, are
highly demanding for CSF3 in order to sustain their metabolic
flexibility. In fact, while both normal density neutrophils (NDNs)
and LDNs use glucose under nutrient supplements, LDNs are
rapidly adapting to metabolic changes, like nutrient/glucose
deprivation and hypoxia, and engage oxidative phosphorylation
over glycolysis. Interestingly, the authors showed that pro-
liver metastatic LDN-MDSC-like cells undertake mitochondrial
metabolism to produce ATP, while NDNs use mitochondria
to regulate apoptosis rather than producing ATP. Moreover,
LDN-MDSC-like cells, were shown to perform NETosis to an
extended degree than NDNs, using lipids as a source, in glucose
deprived environments (i.e., metastatic liver). Indeed, LDNs were
reported to have higher levels of lipids than their counterpart
NDNs, providing fuel to the fatty acid oxidation pathway to
sustain their high metabolic demand required for functional
activity (mainly NETosis). Finally, under glucose and nutrient
limitation, LDN-MSDC-like cells were shown to use glutamate
and proline to induce NETosis. Interestingly, glutaminase, the
TABLE 1 | Myeloid-derived suppressor cells targeting.
Target Class Name Clinical trial
CCR5 Antibody, small molecules Leronlimab, maraviroc, vicriviroc NCT03631407; NCT03838367;
NCT03631407
CCR5-Ig Antibody
CXCR2 Antibody
CD21 Antibody
CSF-R1 Small molecule PLX647
CXCR1/2 Small molecule SX-682 NCT03161431
CXCR4 Small molecule
STAT3 Different molecules Naringenin (SOCS3); ruxolitinib
(phosphorylation); STA-21
(dimerization); Stattic
(phosphorylation); S31–201
(dimerization); AZD9150; MMPP
(DNA binding); siRNA
NCT02417753;
PDE5 Small molecule tadalafil NCT02544880; NCT01697800
HDAC Small molecule Entinostat NCT03250273
ARG1 Small molecule; vaccine CB-1158; ARG1 peptides NCT02903914; NCT03837509;
NCT03689192
IDO Small molecule Epacadostat; BMS-986205 NCT04047706; NCT01961115
c-FLIP Chemotherapy 5-FU
PD-1 Antibody Nivolumab, pembrolizumab NCT03302247; NCT03161431;
NCT03631407
PD-L1 Antibody Durvalumab, atezolimumab NCT02827344
Fatty acids Small molecule Etoxomir
Protein nitration Small molecule Nitroaspirin
COX-2 Small molecule Celecoxib; SC58236, SC58125 NCT02432378
ROS scavengers Small molecules Synthetic triterpenoids
NO donor Small molecule AT38
TRAIL-R2 Antibody DS-8273a NCT02991196
MMP9 Small molecule
Amino-bisphosponates Small molecule Zoledronate
TK Small molecule Sunitinib; axitinib; imatinibe; nilotinib NCT03214718
All-trans retinoic acid Small molecule Vesanoid NCT02403778
Vitamin D3 Vitamin
DNA Chemotherapy Docetaxel
DNA Chemotherapy Gemcitabine NCT03302247; NCT02538432
c-KIT Small molecule Imatinib NCT00852566
VEGF-A Antibody Bevacizumab NCT02669173; NCT02090101
histamine receptor 2 (H2) Small molecule Ranitidine; famotidine NCT03145012
The MDSCs recruitment (blue section), immunosuppression (green section) and maturation /differentiation (orange section) are altered by targeting specific molecules. Targets and
corresponding class and name of inhibitors identified and tested both in vitro and preclinical studies are highlighted. The clinical trial codes, for some of the drugs being tested to target
MDSCs in cancer patients, are indicated.
Frontiers in Oncology | www.frontiersin.org 10 February 2020 | Volume 10 | Article 165
Trovato et al. MDSC and Metastases
enzyme involved in glutamate degradation, is stored inside the
secondary granules, which are secreted upon NET induction.
This could explain why LDN-MDSC-like cells prefer to convert
glutamate to α-ketoglutarate to fuel the tricarboxylic acid (TCA),
during glucose deprivation, rather than protein synthesis. In
conclusion, pro-metastatic PMN-MDSCs are endowed with high
metabolic flexibility to adapt to different microenvironments.
This flexibility mainly resides in the use of lipids to carry out their
functions, including NETosis and cytokine secretion.
CONCLUDING REMARKS
Despite the extraordinary clinical achievements of
immunotherapy on controlling metastatic diseases, our
knowledge about molecular mechanisms and cell-networks
that guide the metastatic process is still limited. Cancer cells
are not an isolated and completely independent entity, but,
in contrast, they act in concert with various cells in the body.
By reprogramming myelopoiesis, cancer cells generate the
“partners in crime,” like MDSCs. As described, MDSCs guide
several aspects of tumor growth and metastatic cascade, such
as cancer cell-stemness, immunosuppression, local invasion,
angiogenesis, vasculogenesis, EMT/MET, CTC-protection and
pMN formation; therefore, we can envision their use as targets to
develop both innovative liquid biopsy-based cancer diagnostics
as well as anti-cancer therapeutic approaches. To date MDSC-
targeting approaches were preferentially validated to contrast
primary tumor growth by acting on three main aspects of MDSC
biology: MDSC trafficking and accumulation in primary tumor,
MDSC functions and MDSC maturation/differentiation from
BM precursors (Table 1). Basically, the abrogation of MDSC
migration inside tumor are based on antagonist antibodies
for specific chemokine receptors [i.e., CXCR2 (192); CCR5
(193)] or small molecules [i.e., CXCR4 (194)]; on the contrary,
strategies targeting the immunosuppressive functions of MDSCs
are based on specific pharmacological inhibitors abrogating
the activity of transcriptional factors [i.e., STAT3 (31)] or key
immunosuppressive-associated enzymes [i.e., COX-2 (82)],
as well as on checkpoint inhibitors [i.e., PD-1L (85)]. Finally,
various type of treatments, including conventional chemotherapy
[i.e., Gemcitabine (38)], small molecules [i.e., sunitinib (195)] or
biological agents [i.e., bevacizumab (196)] have been validated
to limit the MDSC accumulation on tumor site or lymphoid
organs. Interestingly, all these anti-MDSC treatments might
be applied also to limit the metastatic process. In fact, the
possibility to combine checkpoint-based immunotherapy with
MDSC-targeting approaches may be the clinical standard goal
in the near future to develop a personalized cancer therapy. The
use of spontaneous metastatic mouse models able to recapitulate
the biological features of the metastatic spread, the application
of high throughput technologies able to deeply characterize
the genetic, epigenetic and metabolic pathways as well as the
identification of molecules that sustain the cross-talk between
MDSCs and cancer cells, will clarify some unsolved aspects of
the interaction between MDSCs and metastases and lay the
groundwork to design more effective therapeutic strategies.
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